ST. LOUIS, MO – /PRNewswire/ Sept. 8, 2014 — EndoStim, Inc., a medical device company focused on the development and commercialization of a novel neurostimulation system for the treatment of severe gastroesophageal reflux disease (GERD), has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. All of the shares will be offered by the Company.
Wedbush PacGrow Life Sciences is acting as sole book-running manager for the proposed offering, and Craig-Hallum Capital Group and Roth Capital Partners are operating as co-managers in the proposed offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from Wedbush Securities Inc., Two Embarcadero Center, Suite 600, San Francisco, CA 94111, Attn: ECM Prospectus Department or by calling 415-274-6819.
EndoStim is a medical device company focused on the development and commercialization of a novel neurostimulation system for the treatment of severe gastroesophageal reflux disease, or GERD.
The EndoStim neurostimulation system delivers low energy electrical stimulation to the lower esophageal sphincter, or LES, a muscle at the junction of the esophagus and stomach, thereby treating the main cause of GERD — a dysfunctional LES.
EVC Group, Inc.,
Doug Sherk / Brian Moore,